<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2754">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394377</url>
  </required_header>
  <id_info>
    <org_study_id>002/2020</org_study_id>
    <nct_id>NCT04394377</nct_id>
  </id_info>
  <brief_title>Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial</brief_title>
  <acronym>ACTION</acronym>
  <official_title>Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brazilian Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sirio-Libanes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Moinhos de Vento</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Alemão Oswaldo Cruz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beneficência Portuguesa de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brazilian Research In Intensive Care Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brazilian Clinical Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pragmatic randomized clinical trial of patients admitted to the hospital with confirmed
      COVID-19 infection and elevated D-Dimer.

      Randomization 1:1 - Group 1 will undergo a routine full anticoagulation (oral or parenteral
      when needed) strategy; and group 2 will receive usual standard of care with prophylactic
      anticoagulation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who meet the eligibility criteria (patients admitted to hospital with confirmed
      COVID-19 infection associated to D-dimer &gt; 3 times the ULN) will be invited to participate in
      the proposed study and, following the application of the informed consent form, will be
      randomized to 2 groups in the 1:1 ratio. Group 1 will follow the strategy of routine use of
      full anticoagulation therapy (oral or parenteral); and group 2 will follow the usual standard
      care without full anticoagulation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.</measure>
    <time_frame>In 30 days</time_frame>
    <description>The primary objective will be analyzed using the win ratio approach comparing every participant of treatment group to every participant of control group to determine a winner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Venous thromboembolism</measure>
    <time_frame>In 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute myocardial infarction</measure>
    <time_frame>In 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stroke</measure>
    <time_frame>In 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days using oxygen therapy</measure>
    <time_frame>In 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak of troponin</measure>
    <time_frame>In 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak of D-dimer</measure>
    <time_frame>In 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major bleeding and clinically relevant non-major bleeding by the ISTH criteria</measure>
    <time_frame>In 30 days</time_frame>
    <description>It will be considered the main safety endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The routine full anticoagulation strategy will be applied for 30 days. In this strategy, full anticoagulation therapy will be maintained for all patients randomized to group 1 and, depending on the patient's clinical condition, there will be 2 possible routes of administration (oral or parenteral):
Oral: Rivaroxaban 20 mg 1 x daily (adjust the dose to 15 mg 1x daily if ClCr between 30 and 49ml/min and/or concomitant use of azithromycin);
Parenteral: Enoxaparin 1 mg/kg every 12 hours subcutaneously or Unfractionated heparin (preferable option for patients progressing with disseminated intravascular coagulation).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this group will receive the usual standard management and currently have no indication of full anticoagulation. Venous thromboembolism (VTE) prophylaxis should be used in group 2 (usual standard of care) as recommended by guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed</intervention_name>
    <description>Routine full anticoagulation strategy</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2: control group with enoxaparin 40mg/d</intervention_name>
    <description>Usual standard of care and currently have no indication of full anticoagulation.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed diagnosis of COVID-19 admitted to hospital;

          -  Onset of symptoms leading to hospitalization &lt;14 days;

          -  Patients ≥ 18 year old;

          -  D-dimer ≥ 3 x the upper limit of normal;

          -  Agreement to participate by providing the informed consent form (ICF).

        Exclusion Criteria:

          -  Patients with indication for full anticoagulation during inclusion (for example,
             diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve
             prosthesis);

          -  Platelets &lt; 50,000 /mm3

          -  Need for ASA therapy &gt; 100 mg;

          -  Need for P2Y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel);

          -  Chronic use of non-hormonal anti-inflammatory drugs;

          -  Sustained uncontrolled systolic blood pressure (BP) of ≥180 mmHg or diastolic BP of
             ≥100 mmHg;

          -  INR &gt; 1,5;

          -  Patients contraindicated to full anticoagulation (active bleeding, liver failure,
             blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator);

          -  Criteria for disseminated intravascular coagulation (DIC);

          -  A history of hemorrhagic stroke or any intracranial bleeding at any time in the past
             or current intracranial neoplasm (benign or malignant), cerebral metastases,
             arteriovenous (AV) malformation, or aneurysm;

          -  Active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission
             or requiring active chemotherapy or adjunctive therapies such as immunotherapy or
             radiotherapy;

          -  Hypersensitivity to rivaroxaban;

          -  Use of strong inhibitors of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp)
             (e.g. protease inhibitors, ketoconazole, Itraconazole) and/or use of P-gp and strong
             CYP3A4 inducers (such as but not limited to rifampin/rifampicin, rifabutin,
             rifapentine, phenytoin, phenobarbital, carbamazepine, or St. John's Wort);

          -  Known HIV infection;

          -  Creatinine clearance &lt; 30 ml/min according to the Cockcroft-Gault Formula;

          -  Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato D. Lopes, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>BCRI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renato D. Lopes, MD, PhD</last_name>
    <phone>55 11 5904 7339</phone>
    <email>renato.lopes@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Estudos Clínicos do Hospital Cárdio Pulmonar</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz Eduardo Fonteles Ritt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Ensino e Pesquisa do Hospital da Bahia</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna M. Andrade Dracoulakis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilson Soares Feitosa Filho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Maternidade São Vicente de Paulo</name>
      <address>
        <city>Barbalha</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meton Soares de Alencar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Ensino e Aperfeiçoamento em Pesquisa - CEAP</name>
      <address>
        <city>Serra</city>
        <state>Espirito Santo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priscilla de Aquino Martins, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Cardiológicas de Goiânia do Hospital das Clínicas (UFG)</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aguinaldo F. de Freitas Junior, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vera Cruz</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estêvão Lanna Figueiredo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Núcleo de Ciências de Saúde - Unidade de Pesquisa - Hospital Felício Rocho</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Meira de Faria, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário da Universidade Estadual de Londrina</name>
      <address>
        <city>Londrina</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manoel Fernandes Canesin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Agamenon Magalhães</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>João Batista M. Xavier de Moraes Júnior, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Moinhos de Vento</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Basso Gazzana, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Hans Dieter Schmidt</name>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conrado Roberto Hoffmann Filho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - Unesp</name>
      <address>
        <city>Botucatu</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Aparecido Rios Queiroz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Pesquisa Médica</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caio Cesar Ferreira Fernandes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de Votuporanga</name>
      <address>
        <city>Votuporanga</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Esteves Hernandes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Naval Marcílio Dias</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Cés de Souza Dantas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BP - A Beneficência Portuguesa de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane Cordeiro Veiga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hcor - Hospital do Coração</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Biasi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remo Holanda de Mendonça Furtado, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Moriah</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leandro Echenique, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Samaritano Paulista</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lívia Maria Garcia Melro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Paula</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otávio Celso Eluf Gebara, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flávia Ribeiro Machado, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Idelzuita Leandro Liporace, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Assistência Médica ao Servidor Público Estadual de S. Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Bruno Biagioni, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV2</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Coronavirus infection</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

